Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture
AffiliationCell Division Group, CRUK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, UK.
MetadataShow full item record
AbstractEach approach used to synchronize cell cycle progression of human cell lines presents a unique set of challenges. Induction synchrony with agents that transiently block progression through key cell cycle stages are popular, but change stoichiometries of cell cycle regulators, invoke compensatory changes in growth rate and, for DNA replication inhibitors, damage DNA. The production, replacement or manipulation of a target molecule must be exceptionally rapid if the interpretation of phenotypes in the cycle under study is to remain independent of impacts upon progression through the preceding cycle. We show how these challenges are avoided by exploiting the ability of the Cdk4/6 inhibitors, palbociclib, ribociclib and abemaciclib to arrest cell cycle progression at the natural control point for cell cycle commitment: the restriction point. After previous work found no change in the coupling of growth and division during recovery from CDK4/6 inhibition, we find high degrees of synchrony in cell cycle progression. Although we validate CDK4/6 induction synchronization with hTERT-RPE-1, A549, THP1 and H1299, it is effective in other lines and avoids the DNA damage that accompanies synchronization by thymidine block/release. Competence to return to cycle after 72 h arrest enables out of cycle target induction/manipulation, without impacting upon preceding cycles.
CitationTrotter EW, Hagan IM. Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture. Open Biol. 2020;10(10):200200.
- Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
- Authors: Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK
- Issue date: 2017 Jul 4
- Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
- Authors: Spring LM, Zangardi ML, Moy B, Bardia A
- Issue date: 2017 Sep
- Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
- Authors: Kwapisz D
- Issue date: 2017 Nov
- Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
- Authors: Roskoski R Jr
- Issue date: 2016 May
- CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
- Authors: Eggersmann TK, Degenhardt T, Gluz O, Wuerstlein R, Harbeck N
- Issue date: 2019 Apr